Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Assets (2019 - 2025)

Revolution Medicines has reported Other Non-Current Assets over the past 7 years, most recently at $24.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $24.1 million for Q4 2025, up 1286.22% from a year ago — trailing twelve months through Dec 2025 was $24.1 million (up 1286.22% YoY), and the annual figure for FY2025 was $24.1 million, up 1286.22%.
  • Other Non-Current Assets for Q4 2025 was $24.1 million at Revolution Medicines, up from $4.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for RVMD hit a ceiling of $24.1 million in Q4 2025 and a floor of $725000.0 in Q2 2022.
  • Median Other Non-Current Assets over the past 5 years was $2.1 million (2023), compared with a mean of $4.2 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 75.23% in 2024 and later skyrocketed 1286.22% in 2025.
  • Revolution Medicines' Other Non-Current Assets stood at $1.7 million in 2021, then changed by 0.0% to $1.7 million in 2022, then surged by 304.84% to $7.0 million in 2023, then tumbled by 75.23% to $1.7 million in 2024, then skyrocketed by 1286.22% to $24.1 million in 2025.
  • The last three reported values for Other Non-Current Assets were $24.1 million (Q4 2025), $4.9 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.